[Ambulatory treatment of deep venous thrombosis. From data of a study of 108 patients, an evaluation of its cost and its efficacy]

Phlebologie. 1992 Nov-Dec;45(4):447-51.
[Article in French]

Abstract

The study deals with the efficiency and the cost of an ambulatory treatment of deep venous thrombosis by means of Fraxiparine, contention and phlebotonics. 108 patients have been treated. The thrombosis affected the deep veins of the leg in 26 p. cent, the popliteal vein in 9.2 p. cent, the femoropopliteal axis in 19 p. cent as well as superficial thrombosis extended to the depth in 16.6 p. cent. The diagnosis was performed clinically and by ultrasound when phlebography was used in a few cases only (7.4 p. cent). The initial treatment lasted 9.8 days (75 p. cent) 15 days (12 p. cent) and more (12.8 p. cent). Complete re-permeabilization has been noticed in 35.8 p. cent on the 10th day, in 57.5 between the 15th and 30th day. Beside some minor complications 2 recurrences of the thrombosis occurred and 2 patients presented Pulmonary Embolism. They were sent to hospital. The average cost for a treatment was 789 FF for consultation, 1,818 FF for nursing, 1,405 FF for Fraxiparine and 325 FF for contention.

Conclusion: hospitalization is sometimes indispensable, sometimes avoidable ... let us make a good choice.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Ambulatory Care
  • Bandages* / economics
  • Combined Modality Therapy
  • Costs and Cost Analysis
  • Female
  • Femoral Vein / pathology
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / economics
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Heparin, Low-Molecular-Weight / economics
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Popliteal Vein / pathology
  • Pulmonary Embolism / etiology
  • Saphenous Vein / pathology
  • Thrombophlebitis / drug therapy*
  • Thrombophlebitis / economics
  • Thrombophlebitis / pathology
  • Thrombophlebitis / therapy

Substances

  • Fibrinolytic Agents
  • Heparin, Low-Molecular-Weight